A Phase 2 interventional study of BNT162b2s01 and BNT162b2 in COVID-19 and SARS-CoV-2 Infection, sponsored by BioNTech SE. Completed at 4 sites in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by BioNTech SE · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.
Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 43rd largest by enrollment, is one of 30 that started in 2021, is one of 16 in phase 2, and was the 19th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Technical University of Munich · Sites in Austria, Belgium, Germany and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
PharmaJet, Inc. · Sites in United States
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 23 · Phase 4 11
First in 2020; this study’s year is marked. 30 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 137 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 575 across the 54 interventional studies. Of the 39 that completed or were terminated, 28 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
35 studies in COVID-19 by BioNTech SE: 2 open now, 2 under way, 1 of them phase 3. Of 31 finished, 25 (81%) have results posted.
Among the 35 studies in COVID-19 by BioNTech SE, this one is the 30th largest by enrollment, is one of 10 that started in 2021, is one of 6 in phase 2, and was the 19th registered.
BioNTech SE’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing BNT162 Vaccine in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07730450BioNTech SEA Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | 2027-08-20 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing BNT162 Vaccine in COVID-19, from their registry updates:
Among BioNTech SE’s 35 in COVID-19:
This tab as a report to print or save as PDF → With an account.
Trial to evaluate the safety and immunogenicity of one or two boosting doses of Comirnaty or one dose of BNT162b2s01 (Variant of concern [VOC] strain B.1.351) in BNT162-01 trial participants, or two boosting doses of Comirnaty in BNT162-04 trial participants.
Trial participants from BNT162-01 who received two injections of 30 μg Comirnaty were randomized 2:1 to one booster injection (BNT162b2s01: Comirnaty). Trial participants in either the trial BNT162-01 or BNT162-04 who did not receive the full two vaccinations of 30 μg Comirnaty were offered two injections of 30 μg Comirnaty as per the conditional marketing authorization. All potential rollover volunteers must enroll in this trial within less than 18 months of their last injection of a BNT162 candidate vaccine in the parent BNT162-01 or BNT162-04 trials.
Group A trial participants were randomized 2:1 to BNT162b2s01:Comirnaty. Group B trial participants were allocated to trial treatment without active randomization and selected participants were asked to participate in the detailed immunogenicity assessment based on their parent trial cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Trial participants from BNT162-01 (excluding transplant participants from Cohort 13) who received two injections of 30 μg BNT162b2 (Comirnaty) in the parent trial received one booster injection of BNT162b2s01 on Day 1. Day 1 (baseline in this trial) must have occurred ≥24 weeks after the last BNT162b2 (Comirnaty) injection in the parent BNT162-01 trial.
Biological: BNT162b2s01
Trial participants from BNT162-01 (excluding transplant participants from Cohort 13) who received two injections of 30 μg BNT162b2 (Comirnaty) in the parent trial received one booster injection of BNT162b2 (Comirnaty) on Day 1. Day 1 (baseline in this trial) must have occurred ≥24 weeks after the last BNT162b2 (Comirnaty) injection in the parent BNT162-01 trial.
Biological: BNT162b2
Trial participants in either the trial BNT162-01 (excluding transplant participants from Cohort 13) or BNT162-04 who did not receive the full two vaccinations of 30 μg BNT162b2 (Comirnaty) in the respective parent trial were offered two injections of 30 μg BNT162b2 (Comirnaty) as per the conditional marketing authorization on Day 1 and Day 21. Day 1 (baseline in this trial) must have occurred ≥12 weeks after receiving the last BNT162 candidate vaccine in the respective parent BNT162-01 or BNT162-04 trial.
Biological: BNT162b2
Transplant trial participants from Cohort 13 of the trial BNT162-01 received one injection of 30 μg BNT162b2 (Comirnaty) on Day 1 which was followed 3 to 7 months afterward by a second injection of BNT162b2 (Comirnaty). Day 1 (baseline in this trial) must have occurred ≥12 weeks after receiving the last BNT162 candidate vaccine in the parent BNT162-01 trial.
Biological: BNT162b2
intramuscular (IM) injection
IM injection
Also known as: Comirnaty
The Number and Percentage of Participants in Each Treatment Group With at Least One Serious Adverse Event (SAE) or Adverse Events of Special Interest (AESIs)
For treatment-emergent SAEs and AESIs (TESAEs, TEAESIs), the data refers to the interval "Dose 1 up to 28 days after Dose 1". For other SAEs and AESIs, the data refers to the interval "Dose 1 up to 26 weeks after Dose 1". A TESAE/TEAESI is defined as any SAE/AESI with an onset after the first IMP dose or worsened after the first IMP dose (if the SAE/AESI was present before the first administration of IMP). SAEs/AESIs with an onset date more than 28 days after the last administration of IMP will be considered as TESAE/TEAESI only if assessed as related to IMP by the investigator. Participants of the Group B immunology subset are also included in the respective Group B arms and therefore counted in more than one arm/group. Overall a total of 137 participants were enrolled into this study (including the Group B immunology subset participants).
Time frame: Up to 26 weeks after the first IMP injection
The Number and Percentage of Participants With Solicited Local Reactions at the Injection Site Recorded up to 7 Days After Each IMP Injection for Group A and for a Selected Subset (Immunology Subset) of Group B Participants.
Local reactions (pain, tenderness, erythema/redness, induration/swelling) were graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials"; the guidance uses the Grades 1 (mild), 2 (moderate), 3 (severe), and 4 (potentially life-threatening). The reporting of local reactions was based on the participant's assessments via daily solicited reports in the participant diaries. Participants of the Group B immunology subset are part of the Group B. The 'Total' arms include all participants from the respective Group A and Group B immunology subset arms presented.
Time frame: Group A: From Day 1 to Day 8; For Group B (except transplant participants): From Day 1 to Day 8 for Dose 1, and from Day 22 to Day 29 for Dose 2. For Group B transplant participants: From Day 1 to Day 8 for Dose 1, and up to 7 days after Dose 2.
The Number and Percentage of Participants With Solicited Systemic Reactions Recorded up to 7 Days After Each IMP Injection for Group A and for a Selected Subset (Immunology Subset) of Group B Participants.
Systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills and fever) were graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials"; the guidance uses the Grades 1 (mild), 2 (moderate), 3 (severe), and 4 (potentially life-threatening). The reporting of systemic reactions was based on the participant's assessments via daily solicited reports in the participant diaries. Participants of the Group B immunology subset are part of the Group B. The 'Total' arms include all participants from the respective Group A and Group B immunology subset arms presented.
Time frame: Group A: From Day 1 to Day 8; For Group B (except transplant participants): From Day 1 to Day 8 for Dose 1, and from Day 22 to Day 29 for Dose 2. For Group B transplant participants: From Day 1 to Day 8 for Dose 1, and up to 7 days after Dose 2.
The Number and Percentage of Participants With at Least One Unsolicited TEAE Occurring up to 28 Days After IMP Injection in Each Treatment Group for Group A and for a Selected Subset (Immunology Subset) of Group B Participants
A TEAE is defined as any AE with an onset after the first IMP injection or worsened after the first IMP injection (if the AE was present before the first administration of IMP). AEs with an onset date more than 28 days after the last administration of IMP will be considered as treatment-emergent only if assessed as related to IMP by the investigator. Participants of the Group B immunology subset are part of the Group B. The 'Total' arms include all participants from the respective Group A and Group B immunology subset arms presented.
Time frame: Group A: Up to 28 days after Dose 1. Group B: Up to 28 days after Dose 1 and up to 28 days after Dose 2.
Neutralizing Antibody Titers From Reference Strain and SARS-CoV-2 Variant B.1.351
For Group A participants and Group B participants (except transplant subjects). Non-transplant participants of the Group B immunology subset are also part of the respective Group B arm and therefore occurring in more than one arm/group. The 'Total' arm for Group A include all participants from the Group A arms/groups.
Time frame: Group A: At baseline (Day 1) and Day 8 and at Week 4 Day 29), Week 12 (Day 85), and Week 26 (Day 182). Group B: At baseline (Day 1) and Day 8 and at Week 3 (Day 22), Week 4 (Day 29), Week 7 (Day 50), Week 12 (Day 85), and Week 26 (Day 182).
Antibody Titers (ELISA) to Recombinant S1 and RBD Protein Derived From Reference and SARS-CoV-2 Variant B.1.351
For Group A participants and Group B participants (except transplant subjects). Non-transplant participants in the Group B immunology subset arm are also part of the respective Group B arm and therefore occurring in more than one arm/group. The 'Total' arm for Group A include all participants from the Group A arms/groups.
Time frame: Group A: At baseline (Day 1) and Day 8 and at Week 4 Day 29), Week 12 (Day 85), and Week 26 (Day 182). Group B: At baseline (Day 1) and Day 8 and at Week 3 (Day 22), Week 4 (Day 29), Week 7 (Day 50), Week 12 (Day 85), and Week 26 (Day 182).
SARS-CoV-2 Functional Cross-neutralization (GMT Ratios) of Variant B.1.351 to Reference Strain
For Group A only. The geometric mean titer (GMT) ratio is calculated as the GMT of reference divided by the GMT of variant B.1.351. The 'Total' arm for Group A include all participants from the two Group A arms/groups.
Time frame: Up to 26 weeks after the first IMP injection (Dose 1)
Neutralizing Antibody Titers (Reference Strain) Derived From SARS-CoV-2
For Group B transplant subjects, assessed at baseline (Day 1 of Dose 1) and then Day 8, Weeks 4, 12, and 26 post Dose 1, and at Dose 2 (Day 1) and the Day 8, Weeks 4, 12, and 26 post Dose 2. Because the 11 participants of the arm 'Group B Immunology Subset Transplant Participants' are the same 11 participants of the arm 'Group B Immunology Subset Transplant Participants', data is not presented for this arm to avoid duplication of data.
Time frame: From baseline (Day 1 of Dose 1) up to 26 weeks after Dose 2
Antibody Titers (ELISA) (Reference Strain) to Recombinant S1 and RBD Protein Derived From SARS-CoV-2
For Group B transplant subjects, assessed at baseline (Day 1 of Dose 1) and then Day 8, Weeks 4, 12, and 26 post Dose 1, and at Dose 2 (Day 1) and the Day 8, Weeks 4, 12, and 26 post Dose 2. Because the 11 participants of the arm 'Group B Immunology Subset Transplant Participants' are the same 11 participants of the arm 'Group B Immunology Subset Transplant Participants', data is not presented for this arm to avoid duplication of data.
Time frame: From baseline (Day 1 of Dose 1) up to 26 weeks after Dose 2
This rollover study (BNT162-14) has enrolled BNT162-01 (NCT04380701) or BNT162-04 (NCT04537949) study participants meeting all inclusion/exclusion criteria defined in the study protocol. The first participant was enrolled on 26 JUL 2021. The last visit of the last participant was on 16 SEP 2022.
| Milestone | Group A Comirnaty | Group A BNT162b2s01 | Group B Non-transplant Participants | Group B Transplant Participants | Group B Immunology Subset Non-transplant Participants | Group B Immunology Subset Transplant Participants |
|---|---|---|---|---|---|---|
| Started | 21 | 44 | 61 | 11 | 0 | 0 |
| Completed | 21 | 44 | 60 | 9 | 0 | 0 |
| Not completed | 0 | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Non-study sars-cov-2 vaccination | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Group A Comirnaty | Group A BNT162b2s01 | Group B Non-transplant Participants | Group B Transplant Participants | Group B Immunology Subset Non-transplant Participants | Group B Immunology Subset Transplant Participants |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 22 | 11 |
| Completed | 0 | 0 | 0 | 0 | 21 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 2 |
| Withdrew: Non-study sars-cov-2 vaccination | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 |
For treatment-emergent SAEs and AESIs (TESAEs, TEAESIs), the data refers to the interval "Dose 1 up to 28 days after Dose 1". For other SAEs and AESIs, the data refers to the interval "Dose 1 up to 26 weeks after Dose 1". A TESAE/TEAESI is defined as any SAE/AESI with an onset after the first IMP dose or worsened after the first IMP dose (if the SAE/AESI was present before the first administration of IMP). SAEs/AESIs with an onset date more than 28 days after the last administration of IMP will be considered as TESAE/TEAESI only if assessed as related to IMP by the investigator. Participants of the Group B immunology subset are also included in the respective Group B arms and therefore counted in more than one arm/group. Overall a total of 137 participants were enrolled into this study (including the Group B immunology subset participants).
| Participants | Group A Comirnaty | Group A BNT162b2s01 | Group A Total | Group B Non-transplant Participants | Group B Transplant Participants | Group B Total | Group B Immunology Subset Non-transplant Participants | Group B Immunology Subset Transplant Participants | Group B Immunology Subset Total |
|---|---|---|---|---|---|---|---|---|---|
| Any SAE | 0 | 2 | 2 | 1 | 4 | 5 | 0 | 4 | 4 |
| Any related SAE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any TESAE | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 |
| Any related TESAE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any AESI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any related AESI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any TEAESI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Local reactions (pain, tenderness, erythema/redness, induration/swelling) were graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials"; the guidance uses the Grades 1 (mild), 2 (moderate), 3 (severe), and 4 (potentially life-threatening). The reporting of local reactions was based on the participant's assessments via daily solicited reports in the participant diaries. Participants of the Group B immunology subset are part of the Group B. The 'Total' arms include all participants from the respective Group A and Group B immunology subset arms presented.
| Participants | Group A Comirnaty | Group A BNT162b2s01 | Group A Total | Group B Immunology Subset Non-transplant Participants | Group B Immunology Subset Transplant Participants | Group B Immunology Subset Total |
|---|---|---|---|---|---|---|
| Dose 1 up to 7 days after Dose 1: Number of participants with any local reaction | 20 | 41 | 61 | 21 | 10 | 31 |
| Dose 1 up to 7 days after Dose 1: Number of participants with any grade >= 3 local reaction | 1 | 2 | 3 | 3 | 1 | 4 |
| Dose 2 up to 7 days after Dose 2: Number of participants with any local reaction | — | — | — | 20 | 5 | 25 |
| Dose 2 up to 7 days after Dose 2: Number of participants with any grade >= 3 local reaction | — | — | — | 4 | 0 | 4 |
Systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills and fever) were graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials"; the guidance uses the Grades 1 (mild), 2 (moderate), 3 (severe), and 4 (potentially life-threatening). The reporting of systemic reactions was based on the participant's assessments via daily solicited reports in the participant diaries. Participants of the Group B immunology subset are part of the Group B. The 'Total' arms include all participants from the respective Group A and Group B immunology subset arms presented.
| Participants | Group A Comirnaty | Group A BNT162b2s01 | Group A Total | Group B Immunology Subset Non-transplant Participants | Group B Immunology Subset Transplant Participants | Group B Immunology Subset Total |
|---|---|---|---|---|---|---|
| Dose 1 up to 7 days after Dose 1: Number of participants with any systemic reaction | 18 | 33 | 51 | 20 | 8 | 28 |
| Dose 1 up to 7 days after Dose 1: Number of participants with any grade >= 3 systemic reaction | 4 | 9 | 13 | 2 | 0 | 2 |
| Dose 2 up to 7 days after Dose 2: Number of participants with any systemic reaction | — | — | — | 17 | 4 | 21 |
| Dose 2 up to 7 days after Dose 2: Number of participants with any grade >= 3 systemic reaction | — | — | — | 7 | 0 | 7 |
A TEAE is defined as any AE with an onset after the first IMP injection or worsened after the first IMP injection (if the AE was present before the first administration of IMP). AEs with an onset date more than 28 days after the last administration of IMP will be considered as treatment-emergent only if assessed as related to IMP by the investigator. Participants of the Group B immunology subset are part of the Group B. The 'Total' arms include all participants from the respective Group A and Group B immunology subset arms presented.
| Participants | Group A Comirnaty | Group A BNT162b2s01 | Group A Total | Group B Immunology Subset Non-transplant Participants | Group B Immunology Subset Transplant Participants | Group B Immunology Subset Total |
|---|---|---|---|---|---|---|
| Dose 1 up to 28 days after Dose 1: Number of participants with any TEAE | 8 | 14 | 22 | 5 | 6 | 11 |
| Dose 1 up to 28 days after Dose 1: Number of participants with any grade >=3 TEAE | 1 | 1 | 2 | 0 | 0 | 0 |
| Dose 2 up to 28 days after Dose 2; Number of participants with any TEAE | — | — | — | 5 | 2 | 7 |
| Dose 2 up to 28 days after Dose 2; Number of participants with any grade >=3 TEAE | — | — | — | 0 | 0 | 0 |
For Group A participants and Group B participants (except transplant subjects). Non-transplant participants of the Group B immunology subset are also part of the respective Group B arm and therefore occurring in more than one arm/group. The 'Total' arm for Group A include all participants from the Group A arms/groups.
| Titer | Group A Comirnaty | Group A BNT162b2s01 | Group A Total | Group B Non-transplant Participants | Group B Immunology Subset Non-transplant Participants |
|---|---|---|---|---|---|
| Response neutralizing antibody titers reference strain - Baseline (Day 1) | 21.4 (13.2 to 34.5) | 21.3 (15.3 to 29.6) | 21.3 (16.4 to 27.7) | 15.6 (11.5 to 21.0) | 13.3 (8.3 to 21.3) |
| Response neutralizing antibody titers variant B.1.351 - Baseline (Day1) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | — | — |
| Response neutralizing antibody titers reference strain - Day 8 | 640.0 (376.6 to 1087.7) | 349.0 (254.5 to 478.6) | 424.5 (322.5 to 558.8) | 729.3 (485.4 to 1095.8) | 1093.4 (719.8 to 1661.0) |
| Response neutralizing antibody titers variant B.1.351 - Day 8 | 285.1 (164.2 to 495.0) | 330.2 (232.3 to 469.5) | 314.9 (235.8 to 420.6) | — | — |
| Response neutralizing antibody titers reference strain - Week 3 (Day 22) | — | — | — | 1085.6 (775.5 to 1519.5) | 1183.0 (738.2 to 1896.0) |
| Response neutralizing antibody titers reference strain - Week 4 (Day 29) | 570.2 (309.3 to 1051.1) | 509.3 (372.4 to 696.6) | 528.2 (399.1 to 699.2) | 1789.7 (1367.3 to 2342.6) | 1868.1 (1278.7 to 2729.3) |
| Response neutralizing antibody titers variant B.1.351 - Week 4 (Day 29) | 271.3 (157.9 to 466.1) | 325.1 (233.2 to 453.3) | 306.6 (232.4 to 404.6) | — | — |
| Response neutralizing antibody titers reference strain - Week 7 | — | — | — | 1386.0 (1054.5 to 1821.6) | 1429.2 (864.5 to 2362.8) |
| Response neutralizing antibody titers reference strain - Week 12 (Day 85) | 371.2 (202.5 to 680.5) | 282.1 (181.0 to 439.8) | 313.9 (221.5 to 444.9) | 1348.3 (992.8 to 1831.1) | 1301.3 (795.2 to 2129.5) |
| Response neutralizing antibody titers variant B.1.351 - Week 12 (Day 85) | 122.9 (65.3 to 231.4) | 259.4 (162.6 to 413.7) | 194.0 (133.0 to 282.9) | — | — |
| Response neutralizing antibody titers reference strain - Week 26 (Day 182) | 336.2 (159.6 to 708.6) | 132.0 (64.6 to 269.7) | 218.4 (130.0 to 366.8) | 659.8 (469.5 to 927.1) | 710.1 (439.5 to 1147.3) |
| Response neutralizing antibody titers variant B.1.351 - Week 26 (Day 182) | 140.2 (60.4 to 325.2) | 129.5 (63.8 to 262.6) | 135.1 (79.3 to 230.3) | — | — |
For Group A participants and Group B participants (except transplant subjects). Non-transplant participants in the Group B immunology subset arm are also part of the respective Group B arm and therefore occurring in more than one arm/group. The 'Total' arm for Group A include all participants from the Group A arms/groups.
| Titer | Group A Comirnaty | Group A BNT162b2s01 | Group A Total | Group B Non-transplant Participants | Group B Immunology Subset Non-transplant Participants |
|---|---|---|---|---|---|
| Response antibody titers IgG RBD Domain reference strain (ELISA) - Baseline (Day1) | 2216.1 (1507.6 to 3257.7) | 2161.4 (1634.7 to 2857.8) | 2178.9 (1748.0 to 2716.1) | 2135.4 (1303.7 to 3497.5) | 2056.4 (1297.3 to 3259.6) |
| Response antibody titers IgG RBD Domain variant B.1.351 (ELISA) - Baseline (Day 1) | 566.5 (370.9 to 865.3) | 588.7 (438.4 to 790.6) | 581.5 (459.5 to 735.8) | — | — |
| Response antibody titers IgG S Protein reference strain (ELISA) - Baseline (Day 1) | 3209.0 (2045.6 to 5033.9) | 2594.7 (1977.5 to 3404.4) | 2779.1 (2210.9 to 3493.2) | 1634.4 (1025.5 to 2605.0) | 1636.2 (885.2 to 3024.5) |
| Response antibody titers IgG S Protein variant B.1.351 (ELISA) - Baseline (Day 1) | 7164.8 (4231.7 to 12130.9) | 9267.9 (6837.3 to 12562.5) | 8528.4 (6572.5 to 11066.5) | — | — |
| Response antibody titers IgG RBD Domain reference strain (ELISA) - Day 8 | NA (NA to NA) | 48945.7 (35518.9 to 67447.9) | NA (NA to NA) | 48805.7 (29759.0 to 80043.1) | NA (NA to NA) |
| Response antibody titers IgG RBD Domain variant B.1.351 (ELISA) - Day 8 | 22903.0 (11936.4 to 43945.2) | 21244.0 (15712.2 to 28723.3) | 21766.4 (16403.7 to 28882.2) | — | — |
| Response antibody titers IgG S Protein reference strain (ELISA) - Day 8 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 45270.4 (27269.8 to 75153.2) | NA (NA to NA) |
| Response antibody titers IgG S Protein variant B.1.351 (ELISA) - Day 8 | 520744.5 (258322.6 to 1049752.6) | 480042.7 (319790.9 to 720599.2) | 492832.1 (348924.0 to 696092.7) | — | — |
| Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 3 | — | — | — | NA (NA to NA) | NA (NA to NA) |
| Response antibody titers IgG S Protein reference strain (ELISA) - Week 3 | — | — | — | NA (NA to NA) | NA (NA to NA) |
| Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 4 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Response antibody titers IgG RBD Domain variant B.1.351 (ELISA) - Week 4 | 18959.7 (11062.8 to 32493.5) | 21082.1 (16052.9 to 27686.8) | 20371.6 (15940.0 to 26035.3) | — | — |
| Response antibody titers IgG S Protein reference strain (ELISA) - Week 4 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Response antibody titers IgG S Protein variant B.1.351 (ELISA) - Week 4 | 394493.5 (198914.7 to 782371.2) | 362296.9 (259569.0 to 505680.9) | 372400.7 (274455.6 to 505299.6) | — | — |
| Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 7 | — | — | — | NA (NA to NA) | NA (NA to NA) |
| Response antibody titers IgG S Protein reference strain (ELISA) - Week 7 | — | — | — | NA (NA to NA) | NA (NA to NA) |
| Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 12 | 23883.9 (15193.4 to 37545.2) | 28535.3 (20676.5 to 39381.0) | 26627.5 (20616.5 to 34391.0) | NA (NA to NA) | NA (NA to NA) |
| Response antibody titers IgG RBD Domain variant B.1.351 (ELISA) - Week 12 | 11106.8 (6446.7 to 19135.5) | 14367.3 (9798.4 to 21066.5) | 12998.8 (9570.3 to 17655.4) | — | — |
| Response antibody titers IgG S Protein reference strain (ELISA) - Week 12 | 50709.2 (33710.6 to 76279.3) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Response antibody titers IgG S Protein variant B.1.351 (ELISA) - Week 12 | 178167.5 (95710.4 to 331663.8) | 305041.0 (196223.1 to 474205.2) | 247480.6 (173229.4 to 353558.0) | — | — |
| Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 26 | 14309.8 (7900.1 to 25920.0) | 8670.5 (5238.9 to 14349.9) | 11355.5 (7717.3 to 16709.0) | 34032.7 (25327.8 to 45729.3) | 38865.2 (23611.8 to 63972.6) |
| Response antibody titers IgG RBD Domain variant B.1.351 (ELISA) - Week 26 | 9829.9 (4948.4 to 19526.7) | 6967.7 (4124.5 to 11770.9) | 8386.3 (5479.1 to 12835.9) | — | — |
| Response antibody titers IgG S Protein reference strain (ELISA) - Week 26 | 27732.0 (15894.6 to 48385.3) | 17049.8 (10185.6 to 28539.8) | 22155.2 (15250.2 to 32186.6) | NA (NA to NA) | NA (NA to NA) |
| Response antibody titers IgG S Protein variant B.1.351 (ELISA) - Week 26 | 142683.7 (67849.2 to 300057.1) | 91825.4 (50843.9 to 165838.9) | 116420.8 (72901.4 to 185919.5) | — | — |
For Group A only. The geometric mean titer (GMT) ratio is calculated as the GMT of reference divided by the GMT of variant B.1.351. The 'Total' arm for Group A include all participants from the two Group A arms/groups.
| GMT ratio | Group A Comirnaty | Group A BNT162b2s01 | Group A Total |
|---|---|---|---|
| Day 1 - Response neutralizing antibody titers - GMT ratio | 3.1 | 3.0 | 3.0 |
| Day 1 - Response antibody titers IgG RBD Domain - GMT ratio | 3.9 | 3.7 | 3.7 |
| Day 1 - Response antibody titers IgG S Protein - GMT ratio | 0.4 | 0.3 | 0.3 |
| Day 8 - Response neutralizing antibody titers - GMT ratio | 2.2 | 1.1 | 1.3 |
| Day 8 - Response antibody titers IgG RBD Domain - GMT ratio | 2.9 | 2.3 | 2.5 |
| Day 8 - Response antibody titers IgG S Protein - GMT ratio | 0.2 | 0.2 | 0.2 |
| Week 4 (Day 29) - Response neutralizing antibody titers - GMT ratio | 2.1 | 1.6 | 1.7 |
| Week 4 (Day 29) - Response antibody titers IgG RBD Domain - GMT ratio | 3.1 | 2.6 | 2.8 |
| Week 4 (Day 29) - Response antibody titers IgG S Protein - GMT ratio | 0.2 | 0.2 | 0.2 |
| Week 12 (Day 85) - Response neutralizing antibody titers - GMT ratio | 3.0 | 1.1 | 1.6 |
| Week 12 (Day 85) - Response antibody titers IgG RBD Domain - GMT ratio | 2.2 | 2.0 | 2.0 |
| Week 12 (Day 85) - Response antibody titers IgG S Protein - GMT ratio | 0.3 | 0.2 | 0.2 |
| Week 26 (Day 182) - Response neutralizing antibody titers - GMT ratio | 2.4 | 1.0 | 1.6 |
| Week 26 (Day 182) - Response antibody titers IgG RBD Domain - GMT ratio | 1.5 | 1.2 | 1.4 |
| Week 26 (Day 182) - Response antibody titers IgG S Protein - GMT ratio | 0.2 | 0.2 | 0.2 |
For Group B transplant subjects, assessed at baseline (Day 1 of Dose 1) and then Day 8, Weeks 4, 12, and 26 post Dose 1, and at Dose 2 (Day 1) and the Day 8, Weeks 4, 12, and 26 post Dose 2. Because the 11 participants of the arm 'Group B Immunology Subset Transplant Participants' are the same 11 participants of the arm 'Group B Immunology Subset Transplant Participants', data is not presented for this arm to avoid duplication of data.
| Titer | Group B Transplant Participants |
|---|---|
| Day 1 of Dose 1 | NA (NA to NA) |
| Day 8 of Dose 1 | 48.3 (13.0 to 179.2) |
| Week 4 (Day 29) of Dose 1 | 124.4 (25.4 to 609.6) |
| Week 12 (Day 85) of Dose 1 | 80.0 (17.1 to 374.8) |
| Week 26 (Day 182) of Dose 1 | 108.9 (23.1 to 513.0) |
| Day 1 pre Dose 2 | 47.6 (7.3 to 311.5) |
| Day 8 post Dose 2 | 142.5 (9.4 to 2160.6) |
| Week 4 (Day 29) post Dose 2 | 452.5 (61.7 to 3317.6) |
| Week 12 (Day 85) post Dose 2 | 142.5 (21.5 to 945.6) |
| Week 26 (Day 182) post Dose 2 | 127.0 (19.7 to 819.1) |
For Group B transplant subjects, assessed at baseline (Day 1 of Dose 1) and then Day 8, Weeks 4, 12, and 26 post Dose 1, and at Dose 2 (Day 1) and the Day 8, Weeks 4, 12, and 26 post Dose 2. Because the 11 participants of the arm 'Group B Immunology Subset Transplant Participants' are the same 11 participants of the arm 'Group B Immunology Subset Transplant Participants', data is not presented for this arm to avoid duplication of data.
| Titer | Group B Transplant Participants |
|---|---|
| Response antibody titers IgG RBD Domain reference strain (ELISA) - Baseline (Day 1 of Dose 1) | 730.5 (157.1 to 3397.0) |
| Response antibody titers IgG S Protein reference strain (ELISA) - Baseline (Day 1 of Dose 1) | 599.1 (117.1 to 3064.9) |
| Response antibody titers IgG RBD Domain reference strain (ELISA) - Day 8 of Dose 1 | 4328.8 (512.9 to 36532.1) |
| Response antibody titers IgG S Protein reference strain (ELISA) - Day 8 of Dose 1 | 5078.0 (528.0 to 48838.3) |
| Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 4 (Day 29) of Dose 1 | 6616.9 (987.7 to 44327.3) |
| Response antibody titers IgG S Protein reference strain (ELISA) - Week 4 (Day 29) of Dose 1 | 7937.6 (1179.2 to 53431.0) |
| Response antibody titers IgG RBD Domain reference strain (ELISA)- Week 12 (Day 85) of Dose 1 | 5065.9 (791.0 to 32443.1) |
| Response antibody titers IgG S Protein reference strain (ELISA) - Week 12 (Day 85) of Dose 1 | 11988.6 (1607.4 to 89413.3) |
| Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 26 (Day 182) of Dose 1 | 10602.6 (2076.7 to 54130.4) |
| Response antibody titers IgG S Protein reference strain (ELISA) - Week 26 (Day 182) of Dose 1 | 19644.7 (5085.2 to 75890.1) |
| Response antibody titers IgG RBD Domain reference strain (ELISA) - Day 1 pre Dose 2 | 3633.0 (506.1 to 26078.1) |
| Response antibody titers IgG S Protein reference strain (ELISA) - Day 1 pre Dose 2 | 5822.9 (894.5 to 37904.8) |
| Response antibody titers IgG RBD Domain reference strain (ELISA) - Day 8 post Dose 2 | 12441.7 (1398.3 to 110702.9) |
| Response antibody titers IgG S Protein reference strain (ELISA) - Day 8 post Dose 2 | 22067.6 (2752.2 to 176945.0) |
| Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 4 (Day 29) post Dose 2 | 13625.0 (2884.8 to 64350.9) |
| Response antibody titers IgG S Protein reference strain (ELISA) - Week 4 (Day 29) post Dose 2 | 34242.9 (7476.0 to 156845.8) |
| Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 12 (Day 85) post Dose 2 | 12265.4 (1706.1 to 88179.1) |
| Response antibody titers IgG S Protein reference strain (ELISA) - Week 12 (Day 85) post Dose 2 | 24015.7 (3852.9 to 149692.4) |
| Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 26 (Day 182) post Dose 2 | 13468.1 (2320.5 to 78167.7) |
| Response antibody titers IgG S Protein reference strain (ELISA) - Week 26 (Day 182) post Dose 2 | 10833.5 (1763.7 to 66543.9) |
Collected over Local reactions/systemic events: within 7 days after each IMP dose; SAEs: from Day 1 (Dose 1) up to Day 182 after Dose 2 (approximately 26 weeks after Dose 2); Other AEs in participants with Dose 2 (Group B): All AEs from Day 1 up to Day 50 and in addition if assessed as IMP-related from Day 50 up to Day 182 after Dose 2; Other AEs in participants without Dose 2 (Group A): All AEs from Day 1 up to Day 29 and in addition if assessed as IMP-related from Day 29 up to Day 182.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A Comirnaty | 0/21 (0%) | 0/21 (0%) | 3/21 (14.3%) |
| Group A BNT162b2s01 | 0/44 (0%) | 2/44 (4.5%) | 7/44 (15.9%) |
| Group A Total | 0/65 (0%) | 2/65 (3.1%) | 10/65 (15.4%) |
| Group B Non-transplant Participants | 0/61 (0%) | 1/61 (1.6%) | 4/61 (6.6%) |
| Group B Transplant Participants | 0/11 (0%) | 4/11 (36.4%) | 7/11 (63.6%) |
| Group B Total | 0/72 (0%) | 5/72 (6.9%) | 11/72 (15.3%) |
| Group B Immunology Subset Non-transplant Participants | 0/22 (0%) | 0/22 (0%) | 4/22 (18.2%) |
| Group B Immunology Subset Transplant Participants | 0/11 (0%) | 4/11 (36.4%) | 7/11 (63.6%) |
| Group B Immunology Subset Total | 0/33 (0%) | 4/33 (12.1%) | 11/33 (33.3%) |
| Event | Group A Comirnaty | Group A BNT162b2s01 | Group A Total | Group B Non-transplant Participants | Group B Transplant Participants | Group B Total | Group B Immunology Subset Non-transplant Participants | Group B Immunology Subset Transplant Participants | Group B Immunology Subset Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis EInfections and infestations | 0/21 | 0/44 | 0/65 | 0/61 | 1/11 | 1/72 | 0/22 | 1/11 | 1/33 |
| Urinary tract infectionInfections and infestations | 0/21 | 0/44 | 0/65 | 0/61 | 1/11 | 1/72 | 0/22 | 1/11 | 1/33 |
| Shunt blood flow excessiveInjury, poisoning and procedural complications | 0/21 | 0/44 | 0/65 | 0/61 | 1/11 | 1/72 | 0/22 | 1/11 | 1/33 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/21 | 0/44 | 0/65 | 0/61 | 1/11 | 1/72 | 0/22 | 1/11 | 1/33 |
| Supraventricular tachycardiaCardiac disorders | 0/21 | 1/44 | 1/65 | 0/61 | 0/11 | 0/72 | 0/22 | 0/11 | 0/33 |
| Hypertensive crisisVascular disorders | 0/21 | 1/44 | 1/65 | 0/61 | 0/11 | 0/72 | 0/22 | 0/11 | 0/33 |
| Chronic sinusitisInfections and infestations | 0/21 | 0/44 | 0/65 | 1/61 | 0/11 | 1/72 | 0/22 | 0/11 | 0/33 |
| Event | Group A Comirnaty | Group A BNT162b2s01 | Group A Total | Group B Non-transplant Participants | Group B Transplant Participants | Group B Total | Group B Immunology Subset Non-transplant Participants | Group B Immunology Subset Transplant Participants | Group B Immunology Subset Total |
|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/21 | 3/44 | 4/65 | 1/61 | 3/11 | 4/72 | 1/22 | 3/11 | 4/33 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/21 | 1/44 | 3/65 | 0/61 | 0/11 | 0/72 | 0/22 | 0/11 | 0/33 |
| NauseaGastrointestinal disorders | 0/21 | 0/44 | 0/65 | 0/61 | 1/11 | 1/72 | 0/22 | 1/11 | 1/33 |
| FatigueGeneral disorders | 0/21 | 2/44 | 2/65 | 1/61 | 1/11 | 2/72 | 1/22 | 1/11 | 2/33 |
| PyrexiaGeneral disorders | 0/21 | 0/44 | 0/65 | 0/61 | 1/11 | 1/72 | 0/22 | 1/11 | 1/33 |
| Urinary tract infectionInfections and infestations | 0/21 | 0/44 | 0/65 | 0/61 | 1/11 | 1/72 | 0/22 | 1/11 | 1/33 |
| Back painMusculoskeletal and connective tissue disorders | 0/21 | 0/44 | 0/65 | 0/61 | 1/11 | 1/72 | 0/22 | 1/11 | 1/33 |
| Muscle tightnessMusculoskeletal and connective tissue disorders | 0/21 | 0/44 | 0/65 | 0/61 | 1/11 | 1/72 | 0/22 | 1/11 | 1/33 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/21 | 0/44 | 0/65 | 0/61 | 1/11 | 1/72 | 0/22 | 1/11 | 1/33 |
| HeadacheNervous system disorders | 0/21 | 1/44 | 1/65 | 2/61 | 0/11 | 2/72 | 2/22 | 0/11 | 2/33 |
| Age, Categorical(Participants) | Group A Comirnaty | Group A BNT162b2s01 | Group B Non-transplant Participants | Group B Transplant Participants | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 17 | 28 | 50 | 11 | 106 |
| >=65 years | 4 | 16 | 11 | 0 | 31 |
| Age, Continuous(years) | Group A Comirnaty | Group A BNT162b2s01 | Group B Non-transplant Participants | Group B Transplant Participants | Total |
|---|---|---|---|---|---|
| Group A | 53.91 ± 15.13 | 55.81 ± 15.20 | — | — | 55.19 ± 15.09 |
| Group B | — | — | 49.17 ± 16.72 | 50.88 ± 11.92 | 49.43 ± 16.02 |
| Sex: Female, Male(Participants) | Group A Comirnaty | Group A BNT162b2s01 | Group B Non-transplant Participants | Group B Transplant Participants | Total |
|---|---|---|---|---|---|
| Female | 9 | 20 | 29 | 5 | 63 |
| Male | 12 | 24 | 32 | 6 | 74 |
| Ethnicity (NIH/OMB)(Participants) | Group A Comirnaty | Group A BNT162b2s01 | Group B Non-transplant Participants | Group B Transplant Participants | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 20 | 44 | 61 | 11 | 136 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group A Comirnaty | Group A BNT162b2s01 | Group B Non-transplant Participants | Group B Transplant Participants | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 0 | 1 |
| White | 21 | 42 | 61 | 11 | 135 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Group A Comirnaty | Group A BNT162b2s01 | Group B Non-transplant Participants | Group B Transplant Participants | Total |
|---|---|---|---|---|---|
| Germany | 21 | 44 | 61 | 11 | 137 |
| Weight(kg) | Group A Comirnaty | Group A BNT162b2s01 | Group B Non-transplant Participants | Group B Transplant Participants | Total |
|---|---|---|---|---|---|
| Group A | 76.76 ± 10.80 | 76.73 ± 13.45 | — | — | 76.74 ± 12.57 |
| Group B | — | — | 76.79 ± 13.86 | 74.14 ± 10.93 | 76.38 ± 13.42 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2021 to primary completion in Apr 2022, 8 months.
Results were first posted in Sep 2024, 2 years 5 months after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 8 months is close to that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BNT162 Vaccine